Evolent Health (EVH) Earning Somewhat Favorable Media Coverage, Analysis Shows

Headlines about Evolent Health (NYSE:EVH) have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Evolent Health earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned news articles about the technology company an impact score of 44.7533772394244 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the media stories that may have impacted Accern’s scoring:

Evolent Health (NYSE EVH) traded down 0.88% during midday trading on Thursday, hitting $16.85. 485,407 shares of the stock were exchanged. Evolent Health has a 12-month low of $14.50 and a 12-month high of $22.10. The stock’s market cap is $1.11 billion. The firm has a 50 day moving average of $17.12 and a 200-day moving average of $17.12.

Evolent Health (NYSE:EVH) last released its quarterly earnings data on Monday, August 7th. The technology company reported ($0.13) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.13). The business had revenue of $107.30 million for the quarter, compared to analysts’ expectations of $104.45 million. Evolent Health had a negative return on equity of 6.44% and a negative net margin of 17.57%. Evolent Health’s quarterly revenue was up 89.9% on a year-over-year basis. During the same period in the previous year, the business posted ($0.20) earnings per share. On average, equities analysts expect that Evolent Health will post ($0.40) earnings per share for the current year.

Several analysts have recently issued reports on EVH shares. Cowen and Company reiterated an “outperform” rating and issued a $35.00 target price on shares of Evolent Health in a research report on Wednesday, June 28th. BidaskClub upgraded shares of Evolent Health from a “buy” rating to a “strong-buy” rating in a research report on Thursday, July 13th. ValuEngine lowered shares of Evolent Health from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Robert W. Baird set a $35.00 target price on shares of Evolent Health and gave the company a “buy” rating in a research report on Tuesday, August 8th. Finally, Zacks Investment Research downgraded shares of Evolent Health from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $28.45.

ILLEGAL ACTIVITY WARNING: “Evolent Health (EVH) Earning Somewhat Favorable Media Coverage, Analysis Shows” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2017/10/26/evolent-health-evh-given-news-impact-rating-of-0-24.html.

In other Evolent Health news, CEO Frank J. Williams sold 16,300 shares of the company’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $23.73, for a total value of $386,799.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Steve Wigginton sold 6,000 shares of the company’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $24.64, for a total value of $147,840.00. The disclosure for this sale can be found here. Corporate insiders own 8.79% of the company’s stock.

Evolent Health Company Profile

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Insider Buying and Selling by Quarter for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply